Peptide Supplements & Sports Recovery: What Research Shows

As peptide supplements continue to flood the sports medicine marketplace, a rigorous new scoping review published in The American Journal of Sports Medicine offers the most comprehensive peer-reviewed assessment to date of six widely used compounds. The study — "Peptide Supplements and Their Therapeutic Applications in Sports Medicine" by Tewari, Liu, Im, and colleagues (2026) — evaluated BPC-157, thymosin beta-4 (TB-500), CJC-1295, MK-677 (ibutamoren), ipamorelin, and GHK-Cu (copper peptide) across both animal and human research models. The findings underscore a critical gap between the bold marketing claims driving this booming industry and the actual evidence available to support them.

What This Study Found

Researchers conducted a systematic scoping review following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, searching the PubMed database using combinations of peptide and musculoskeletal tissue search terms — including bone, fracture, muscle, tendon, ligament, meniscus, and cartilage. Three independent reviewers screened all identified publications.

One of the study's most telling findings was its breakdown of the existing evidence base: 67% of all identified publications utilized preclinical animal models, most commonly rats. While each compound demonstrated unique biological mechanisms and showed variable but often promising effects on tendon, muscle, bone, and ligament healing in these animal studies, the authors caution that preclinical results do not automatically translate to human outcomes.

Human clinical data, by contrast, was notably sparse. The study found only a handful of human investigations, and the researchers characterized most of these as lacking robust controls or rigorous study designs. Where human data did exist, it revealed modest improvements at best — primarily in areas of metabolic bone health and degenerative knee pain — and significant heterogeneity in dosing protocols and routes of administration made cross-study comparisons difficult.

Importantly, the review also surfaced meaningful safety signals. MK-677, in particular, was associated with significant cardiovascular risks, including congestive heart failure. Across the peptide class more broadly, researchers identified documented concerns around metabolic dysfunction, including insulin resistance. These are not trivial adverse effects, especially in athletic populations who may be self-administering these compounds without medical supervision.

Clinical Significance

For sports medicine clinicians, orthopaedic surgeons, and physical therapists, this study delivers a clear and evidence-grounded message: the therapeutic promise suggested by animal research has not yet been validated in well-designed human clinical trials.

The authors concluded that the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials and that peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care (Tewari et al., 2026).

This is a nuanced but critical distinction. The study does not suggest that peptides are without biological plausibility — the mechanistic data from animal models is, in some cases, genuinely intriguing. BPC-157, for instance, has been studied for its potential role in tendon and ligament repair pathways in rodent models. GHK-Cu has shown activity related to tissue remodeling in preclinical settings. But biological plausibility and demonstrated clinical efficacy in humans are not the same thing, and conflating the two poses real risks to patients.

The safety findings are equally significant from a clinical standpoint. Congestive heart failure is a serious outcome. Insulin resistance, particularly in metabolically active athletes, carries its own downstream consequences. Clinicians should be prepared for patients who are already using these peptides — often sourced from unregulated channels — and should be equipped to counsel them using the most current available evidence.

Current Access and Compliance Context

The growth of the peptide supplement market has outpaced regulatory oversight in many respects. Patients and athletes frequently obtain these compounds through online gray-market vendors, compounding pharmacies, or wellness clinics operating outside conventional sports medicine frameworks. Many users perceive peptides as inherently low-risk — a perception the authors of this study directly challenge.

From a regulatory standpoint, several of the peptides reviewed exist in a complex legal landscape. Some have been investigated as pharmaceutical agents (MK-677, for example, has been studied in clinical trials for conditions including muscle wasting and growth hormone deficiency), while others, like BPC-157, remain without any approved human indication in most regulatory jurisdictions. Athletes competing under anti-doping frameworks should also be aware that some of these compounds are prohibited by the World Anti-Doping Agency (WADA), regardless of their commercial availability.

This regulatory ambiguity makes physician-guided evaluation and oversight essential. Patients who are curious about or already using peptide supplements deserve access to qualified medical professionals who can assess individual risk, review relevant research, and make evidence-informed recommendations — rather than relying solely on marketing materials or anecdotal reports.

What Patients Should Know

If you are an athlete, active individual, or patient exploring peptide supplements for recovery or performance, here is what the current science suggests you should understand:

• Most of the promising data is from animal studies. While animal research is an important part of the scientific process, it does not confirm that a treatment will work — or be safe — in humans. The study by Tewari et al. (2026) found that two-thirds of all research on these peptides was conducted in preclinical models.
• Human evidence is limited and mixed. Where human studies do exist, the research suggests only modest potential benefits, and many studies lack the rigorous design needed to draw firm conclusions.
• Real safety risks have been documented. MK-677 has been associated with congestive heart failure in research settings. Insulin resistance is another documented concern. These are serious considerations, not minor side effects.
• Dosing and administration vary widely. There is no established, evidence-based dosing protocol for most of these peptides in humans, which further complicates self-administration outside of a clinical setting.
• Peptides are not a replacement for standard care. The authors of this study explicitly state that peptide supplements should not currently replace or supplement standard orthopaedic treatment approaches.

None of this means the research conversation is closed. The study's authors acknowledge that animal model data warrants continued scientific investigation, and future well-designed human clinical trials may yet clarify which peptides, if any, offer meaningful clinical benefit. But until that evidence exists, patients deserve honest, transparent guidance grounded in what is actually known.

Conclusion

The 2026 scoping review by Tewari, Liu, Im, and colleagues in The American Journal of Sports Medicine is an important contribution to an area where scientific rigor has frequently lagged behind commercial enthusiasm. It reminds us that promising animal data, compelling marketing, and widespread popularity are not substitutes for robust human clinical evidence — and that safety must always be part of the conversation.

At the Peptide Association, we are committed to advancing responsible, evidence-based dialogue about peptide science. We believe patients deserve access to qualified physicians who understand the current research landscape and can provide individualized, informed guidance.

If you are considering peptide therapies or want to discuss the latest research with a qualified medical professional, we encourage you to find a knowledgeable provider through our directory at peptideassociation.org/find-a-doctor.

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content summarizes peer-reviewed research and should not be used as a substitute for consultation with a qualified healthcare provider. Always seek the advice of your physician or other qualified health professional with any questions you may have regarding a medical condition or treatment.

Citation (AMA Format):
Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. doi:10.1177/03635465261464420. PMID: 42578445.